Login / Signup

Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy".

Samuel C R Sherratt
Published in: Circulation (2022)
Keyphrases
  • low density lipoprotein
  • open label
  • double blind
  • placebo controlled
  • phase ii
  • clinical trial
  • combination therapy
  • replacement therapy